

PRODUCT DATA SHEET

Bioworld Technology CO., Ltd.



ABL1 (L406) Peptide

Cat No.: BS3592P

Background

The Abl oncogene was initially identified as the viral transforming gene of Abelson murine leukemia virus (A-MuLV). The major translational product of c-Abl has been identified as a protein with tyrosine kinase activity and an SH2 domain. The Abl oncogene is implicated in several human leukemias including 90-95% of chronic myelocytic leukemia (CML), 20-25% of adult acute lymphoblastic leukemia (ALL) and 2-5% of pediatric ALL. In these leukemias the c-Abl proto-oncogene undergoes a (9;22) chromosomal translocation producing the Philadelphia (Ph1) chromosome. The molecular consequence of this translocation is the generation of a chimeric Bcr/c-Abl mRNA encoding activated Abl protein-tyrosine kinase. The Bcr gene has been shown to encode a GTPase-activating protein (GAP) specific for the Ras-related GTP-binding protein, p21rac.

Swiss-Prot

P00519

Applications

Blocking

Specificity

This peptide can be used with studies using BS3592 ABL1 (L406) pAb.

Purification & Purity

Synthetic peptide ABL1 (L406). (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at 4 °C short term. Aliquot and store at -20 °C long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.